- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Dr. Mark Taubman assumes ATVB journal editorial duties
The American Heart Association and Lippincott Williams & Wilkins, a part of Wolters Kluwer
Health, are pleased to announce that Mark B. Taubman, M.D. has been named editor-in-chief of Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association (ATVB), a monthly journal devoted to the biology, prevention and impact of vascular diseases.
Taubman is the Charles A. Dewey Professor of Medicine, Chairman of
Medicine, and co-director of the Cardiovascular Research Institute at the
University of Rochester, New York. The July 2007 issue of Arteriosclerosis,
Thrombosis, and Vascular Biology, which posted today, is the first under
"I am honored at the opportunity to oversee this outstanding journal,"
Taubman said. "Together with my associate editors, my goals are to
establish ATVB as the leader in vascular biology, as a trendsetter and a
place for exploring new technologies and approaches, and as a site for
publishing comprehensive studies of the highest quality."
As the journal name indicates, Arteriosclerosis, Thrombosis, and
Vascular Biology covers all aspects of new research related to
arteriosclerosis, thrombosis and vascular biology. Each monthly issue
features major new peer- reviewed studies from all disciplines contributing
to the field, with a focus on the scientific advances that will drive
tomorrow's advances in clinical practice.
"Our vision is to provide a forum for presenting cutting-edge
technologies and many new avenues of investigation-such as vascular
development, stem cell research, genomics, proteomics, genetics and
nanotechnology-now being explored by investigators in our three core
disciplines," Taubman said.
In addition to original research, Arteriosclerosis, Thrombosis, and
Vascular Biology is noted for presenting up-to-date reviews on topics of
pressing interest, written by prominent experts in the field. Recent review
-- the connection between adipose (fat) tissue and atherosclerosis;
-- emerging clinical approaches to manipulating angiogenesis (the
formation of new blood vessels); and
-- the contribution of fast food to the rise of obesity and
Arteriosclerosis, Thrombosis, and Vascular Biology also presents
editorials, letters to the editor and other features to keep readers
involved in the worldwide dialogue concerning the development, prevention
and treatment of arteriosclerosis and thrombosis.
Subscribers can access the full text of each issue at the journal's Web
site, atvb.ahajournals.org. Articles of particular importance are posted
online, weeks before print publication in the "ATVBe First" section of the
Web site, allowing even earlier access to major clinical findings.
Subscribers, and readers alike, have access to the journal's expanded
online archive, providing access to the complete history of the
journal-dating back to the first issue in 1981.
"We're looking at opportunities to introduce other types of special
Web- enhanced content in the near future, thus enhancing the value of the
journal to our subscribers and to the vascular community at large," Taubman
Arteriosclerosis, Thrombosis, and Vascular Biology is also available on
the Web site, the world's largest online database of more
than 900 premiere medical journals offered exclusively by Ovid
Technologies, an operating company of the Wolters Kluwer Health division.
"The coming years promise to be an exciting time for scientific
research in all fields related to vascular biology and vascular diseases,"
commented Ivor J. Benjamin, M.D., chairperson of the American Heart
Association's Scientific Publishing Committee. "We are certain that, under
Dr. Taubman's tenure, ATVB will strengthen its position as an indispensable
resource for all scientists involved in vascular research."
About American Heart Association
Founded in 1924, the American Heart Association is the nation's oldest
and largest voluntary health organization dedicated to building healthier
lives, free of cardiovascular diseases and stroke. These diseases,
America's No. 1 and No. 3 killers, claim more than 870,000 lives a year. In
fiscal year 2005- 06 the association invested more than $543 million in
research, professional and public education, advocacy and community service
programs to help all Americans live longer, healthier lives. To learn more,
call 1-800-AHA-USA1 or visit http://www.americanheart.org .
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins ( http://www.LWW.com ) is a leading
international publisher for healthcare professionals and students with
nearly 300 periodicals and 1,500 books in more than 100 disciplines
publishing under the LWW brand, as well as content-based sites and online
corporate and customer services. LWW is part of Wolters Kluwer Health, a
leading provider of information for professionals and students in medicine,
nursing, allied health, pharmacy and the pharmaceutical industry. Wolters
Kluwer Health is a division of Wolters Kluwer, a leading global information
services and publishing company with annual revenues (2006) of €3.7 billion
and approximately 19,900 employees worldwide. Visit
For more information, please click here
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Creating a color printer that uses a colorless, non-toxic ink inspired by nature February 11th, 2016
SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016
Nanoparticle reduces targeted cancer drug's toxicity February 11th, 2016
Cima NanoTech Debuts Large Interactive Touch Screens with European Customers at ISE 2016: For the first time in Europe, Cima NanoTech’s wide range of high performance, projected capacitive touch modules are showcased February 11th, 2016
Semblant Appoints Donald Cunningham as Chief Commercial Officer January 2nd, 2016